Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.

She has an MA in business and economic reporting from New York University. You can connect with Laura on 

Articles

Patients experienced similar safety and efficacy if they received first-line or later-line treatment for unresectable hepatocellular carcinoma (u-HCC). 

Real-World Results of Durvalumab/Tremelimumab in U-HCC Show Promise Despite Line of Therapy

Lauren Biscaldi is the managing editor of Drug Topics

A presentation at the National Community Pharmacists Association Annual Meeting and Exposition focused on the latest on COVID-19 vaccination.

Key Recommendations for 2024-2025 Respiratory Virus Season

Jared is a freelance writer for The American Journal of Managed Care® (AJMC®), and previously worked as a senior editor for HCPLive® at MJH Life Sciences®.

He has an MA from University of Sioux Falls. You can connect with Jared on 

Patients continued taking their medications for pulmonary arterial hypertension (PAH) when symptoms appeared to improve, according to a new survey.

Communication Can Boost Medication Persistence in PAH

Hayden is an assistant editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2021, where she produces written and video content covering multiple disease states.

She has a BA in journalism & media studies from Rutgers University. You can connect with Hayden on 

Further research is needed to determine how once-weekly viltolarsen can slow disease progression and preserve motor function in boys and young men with Duchenne muscular dystrophy (DMD).

Viltolarsen Slows DMD Progression in Small Study

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

Measuring Patient Persistency with Drug Therapy Using Methods for the Design and Analysis of Natural History Studies

Participating Faculty

Introduction

An Economic Analysis of Switching to Latanoprost from a Beta-Blocker or adding Brimonidine or Latanoprost to a Beta-Blocker in Open-Angle Glaucoma or Ocular Hypertension

Population-Based Persistency Rates for Topical Glaucoma Medications Measured with Pharmacy Claims Data

Rates of Discontinuation and Change of Glaucoma Therapy in a Managed Care Setting

Dicontinuation Rates of Topical Glaucoma Medications in a Managed Care Population

Measuring Persistency and Intraocular Pressure-Controlled Days in Patients Receiving Topical Glaucoma Medications